ArticleBone marrow transplantation2018
Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Review
- Patients' symptoms and challenges during the first year after allogeneic haematopoietic cell transplantation-patients' own expressions.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Development and effectiveness evaluation of a mobile health-based follow-up management model for patients after hematopoietic stem cell transplantation.Frontiers in medicine · 2026Article
- Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey.Oncology and therapy · 2024Article
- Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies.Blood advances · 2024Article
- Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors.EJHaem · 2024Article
- Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival.Cardio-oncology (London, England) · 2023Article
- Real-Time Reflectance Confocal Microscopy of Cutaneous Graft-versus-Host Disease Correlates with Histopathology.Transplantation and cellular therapy · 2022Article
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report.Transplantation and cellular therapy · 2021Article
- Late infectious complications in hematopoietic cell transplantation survivors: a population-based study.Blood advances · 2020Article
- Phenotypical diversity of airway morphology in chronic lung graft vs. host disease after stem cell transplantation.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic cell transplantation (HCT) is associated with significant morbidity and mortality especially in the first year after HCT. In this study, we examine the long-term outcomes of patients who survived at least one year post HCT without evidence of relapse. We analyzed the records for 389 consecutive patients receiving an allogeneic transplant from 2005 to 2016 from a MRD, MUD, or haploidentical donor, who were alive and disease free at one year post-transplant. Patient characteristics and outcome parameters were extracted from our institutional database where they had been prospectively entered. A total of 389 patients met the selection criteria with donor graft including MRD 37%, MUD 39%, and Haploidenitcal relative 24%. The median follow-up of survivors from time of HCT was 48.2 months. The median overall survival and disease-free survival at 5 years after the first anniversary post HCT was 78 and 74%, respectively. The most common causes of late mortality were disease relapse, chronic GVHD and infections. The major risk factors for late mortality included chronic GVHD requiring immunosuppression, being transplanted between 2005 and 2009 compared to later years and male sex. Patients with high risk disease risk index (DRI) had worse OS compared to low risk DRI. The risk factors for late relapse included male sex and high/very high disease risk index. The projected long-term survival of 1-year survivors following allogeneic HCT is excellent. However, some patients remain at high risk of late relapse and late mortality. Early referral to transplant, adopting post-transplant consolidation strategies for high risk patients, and implementing newer GVHD prevention methods are potential interventions to help minimize the risk of late relapse and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.